TRV GP III, LLC
- SEC CIK
- 0001637299
- Latest filing
- Feb 14, 2024
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 12, 2021. Long positions only.
- Positions
- 7
- No 13F data for Q4 2020
- Portfolio value
- $790.6M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| RVMDRevolution Medicines, Inc. | COM | 5,524,031 | $253.4M | 32.1% | – | – | History |
| PLRXPliant Therapeutics, Inc. | COM | 5,839,160 | $229.7M | 29.0% | – | – | History |
| NRIXNurix Therapeutics, Inc. | COM | 4,508,333 | $140.2M | 17.7% | – | – | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,962,202 | $70.2M | 8.9% | – | – | History |
| DBTXDecibel Therapeutics, Inc. | COM | 3,139,685 | $35.7M | 4.5% | – | – | History |
| JNCEJounce Therapeutics, Inc. | COM | 3,048,780 | $31.3M | 4.0% | – | – | History |
| VYGRVoyager Therapeutics, Inc. | COM | 6,391,176 | $30.1M | 3.8% | – | – | History |